Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs ; volume:84 ; number:8 ; day:1 ; month:7 ; year:2024 ; pages:877-894 ; date:8.2024
Drugs ; 84, Heft 8 (1.7.2024), 877-894, 8.2024
- Creator
-
Favalli, Ennio Giulio
Maioli, Gabriella
Caporali, Roberto
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40265-024-02059-8
- URN
-
urn:nbn:de:101:1-2411120855343.307746214602
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Favalli, Ennio Giulio
- Maioli, Gabriella
- Caporali, Roberto
- SpringerLink (Online service)
Other Objects (12)
Variability in response to anti-rheumatic drugs
Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis
The Effect of Anti-rheumatic Drugs on the Skeleton
“Life-changing”: the experience of super-responders to biologics in severe asthma
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Evaluation of a patient decision aid for initiating disease modifying anti-rheumatic drugs
Hypersensitivity reactions to biologic disease modifying antirheumatic drugs: experience from the TTSH Singapore biologics registry
Patient participation in decisions about disease modifying anti-rheumatic drugs: a cross-sectional survey
ASPS Exhibits Anti‐Rheumatic Effects by Reprogramming Gut Microbiota and Increasing Serumy‐Glutamylcysteine Leve
Limited effect of anti-rheumatic treatment on 15-prostaglandin dehydrogenase in rheumatoid arthritis synovial tissue
ASPS Exhibits Anti‐Rheumatic Effects by Reprogramming Gut Microbiota and Increasing Serum γ ‐Glutamylcysteine Level
The effect of newer anti-rheumatic drugs on osteogenic cell proliferation: an in-vitro study
Variability in response to anti-rheumatic drugs
Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis
The Effect of Anti-rheumatic Drugs on the Skeleton
“Life-changing”: the experience of super-responders to biologics in severe asthma
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Evaluation of a patient decision aid for initiating disease modifying anti-rheumatic drugs
Hypersensitivity reactions to biologic disease modifying antirheumatic drugs: experience from the TTSH Singapore biologics registry
Patient participation in decisions about disease modifying anti-rheumatic drugs: a cross-sectional survey
ASPS Exhibits Anti‐Rheumatic Effects by Reprogramming Gut Microbiota and Increasing Serumy‐Glutamylcysteine Leve
Limited effect of anti-rheumatic treatment on 15-prostaglandin dehydrogenase in rheumatoid arthritis synovial tissue
ASPS Exhibits Anti‐Rheumatic Effects by Reprogramming Gut Microbiota and Increasing Serum γ ‐Glutamylcysteine Level
The effect of newer anti-rheumatic drugs on osteogenic cell proliferation: an in-vitro study
Variability in response to anti-rheumatic drugs
Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis
The Effect of Anti-rheumatic Drugs on the Skeleton
“Life-changing”: the experience of super-responders to biologics in severe asthma
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Evaluation of a patient decision aid for initiating disease modifying anti-rheumatic drugs
Hypersensitivity reactions to biologic disease modifying antirheumatic drugs: experience from the TTSH Singapore biologics registry
Patient participation in decisions about disease modifying anti-rheumatic drugs: a cross-sectional survey
ASPS Exhibits Anti‐Rheumatic Effects by Reprogramming Gut Microbiota and Increasing Serumy‐Glutamylcysteine Leve
Limited effect of anti-rheumatic treatment on 15-prostaglandin dehydrogenase in rheumatoid arthritis synovial tissue
ASPS Exhibits Anti‐Rheumatic Effects by Reprogramming Gut Microbiota and Increasing Serum γ ‐Glutamylcysteine Level